3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lung Neoplasms
25
Prostatic Neoplasms
23
Carcinoma, Non-Small-Cell Lung
15
Multiple Myeloma
14
Sarcoma
12
Leukemia, Myeloid, Acute
12
Breast Neoplasms
12
Lymphoma, Non-Hodgkin
10
Glioma
10
Wilms Tumor
9
Colorectal Neoplasms
9
Carcinoma, Hepatocellular
9
Rectal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Ovarian Neoplasms
8
Osteosarcoma
8
Neuroblastoma
8
Neoplasm Metastasis
8
Myelodysplastic Syndromes
8
Rhabdomyosarcoma
7
Rhabdoid Tumor
7
Pancreatic Neoplasms
7
Medulloblastoma
7
Hepatoblastoma
7
Neuroectodermal Tumors, Primitive, Peripheral
6
Mouth Neoplasms
6
Melanoma
6
Lymphoma
6
Histiocytosis, Langerhans-Cell
6
Head and Neck Neoplasms
6
Interventions
Cyclophosphamide
151
Dexamethasone
140
Rituximab
83
fludarabine
78
Cytarabine
69
Lenalidomide
68
Bortezomib
63
fludarabine phosphate
62
Gemcitabine
62
venetoclax
54
Etoposide
53
pembrolizumab
52
pomalidomide
48
Paclitaxel
48
Cisplatin
47
Carboplatin
47
Peripheral Blood Stem Cell Transplantation
46
Filgrastim
40
Radiotherapy
39
Calcium Dobesilate
36
Busulfan
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
29
Vincristine
28
Temozolomide
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Recurrence
×
X-Rays
×
Clear all
NCT02636634
2016-04-11
CV-METANEC
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
90 enrolled